Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA

Back

NEDD4: A Promising Target for Cancer Therapy

Author(s): Xiantao Ye, Lixia Wang, Bingxue Shang, Zhiwei Wang and Wenyi Wei

Affiliation: Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave., Boston, MA 02215, USA.

Keywords: Cancer, E3 ligase, NEDD4, oncogene, target, therapy, ubiquitination.

Graphical Abstract:


Abstract:

The Neuronally expressed developmentally downregulated 4 (NEDD4), functioning largely as an E3 ubiquitin ligase, has been demonstrated to play a critical role in the development and progression of human cancers. In this review, to understand the regulatory mechanism(s) of NEDD4 as well as the signaling pathways controlled by NEDD4, we briefly describe the NEDD4 upstream regulators and its downstream ubiquitin substrates. Moreover, we further discuss its oncogenic roles in human malignancies. Therefore, targeting NEDD4 could be a potential therapeutic strategy for treatment of human cancers.

Reprint ePrint Rights & PermissionsPrintExport

Article Details

VOLUME: 14
ISSUE: 6
Page: [549 - 556]
Pages: 8
DOI: 10.2174/1568009614666140725092430